Ets-1 is the prototype of the family of ETS transcription factors. In human tumors, Ets-1 is expressed in endothelial cells and fibroblasts of the tumor stroma and is proposed to play a role in tumor vascularization and invasion by upregulating expression of matrix-degrading proteases. In human carcinomas, Ets-1 is also expressed by neoplastic cells, but little is known about the functional implications of this observation. We have addressed the role of Ets-1 in epithelial HeLa tumor cells by selecting stably Ets-1 over and underexpressing HeLa cells. Ets-1 expression increases the transformed phenotype of HeLa cells, by promoting cell migration, invasion and anchorage-independent growth, while Ets-1 downregulation reduces cell attachment. In correlation with these results, Ets-1 upregulation increases integrinb2 expression but not that of other integrins. These results suggest that, in addition to its role in the tumor stroma, Ets-1 may also promote tumor development and progression by increasing neoplastic transformation.
ETS transcription factors share a specific DNA-binding domain composed of approximately 80 amino acids (ETS domain) (Wasylyk et al., 1993) , which mediates transactivation or repression of numerous target genes (Meraro et al., 2002; Baker et al., 2003; Maurer et al., 2003; Waga et al., 2003) . Among these factors, Ets-1 is expressed in endothelial cells during physiological and, more importantly, pathological conditions such as tumor vascularization and is proposed to play a role in angiogenesis (Vandenbunder et al., 1989; Wernert et al., 1992 Wernert et al., , 1994 Wernert et al., , 1999 Adam et al., 2003; PourtierManzanedo et al., 2003) . We previously showed that ets-1 is expressed in stromal capillary endothelials and fibroblasts of several human carcinomas, in correlation with tumor vascularization and invasion (Wernert, 1997; Wernert et al., 1992 Wernert et al., , 1994 Behrens et al., 2001 Behrens et al., , 2003 . Ets-1 is also expressed in epithelial carcinoma cells, though less frequently than in stromal cells (Wernert et al., 1992 (Wernert et al., , 1994 Behrens et al., 2001) . Little is known about the biological significance of this expression. In human breast cancer cell lines, Ets-1 expression was proposed to be associated with in vitro invasiveness and epithelial -mesenchymal transition, linked to an expression of vimentin, uPA, MMP-1 and MMP-3 and to a loss of E-cadherin (Gilles et al., 1997) . In normal MDCK cells, Ets-1 is a target of scatter factor/ hepatocyte growth factor (SF/HGF) signalling through met receptor tyrosine kinase (Fafeur et al., 1997; Paumelle et al., 2000 Paumelle et al., , 2002 . After stimulation by SF/ HGF, MDCK cells disperse and concomitantly overexpress Ets-1 together with proteases known to play a role in the dispersion of normal and neoplastic cells.
In the present work, we have studied the effects of Ets-1 over and underexpression in the neoplastic epithelial HeLa cells, which are among the most malignant cell lines. HeLa cells were used because Ets-1 expression was reported to be very low in these cells (Bradford et al., 1997; Petrella et al., 1998; Wasylyk et al., 2002) , thus allowing experimental regulation of Ets-1 expression. Two stable HeLa cell cultures were established by transfection with either an Ets-1 or an Ets-1-antisense expression vector. Ets-1-overexpressing (HeLa-Ets-1) and underexpressing (HeLa-invers) cells were selected from pooled populations of transfected cells, in order to avoid clonal variations. Using Western blot analysis, Ets-1 expression corresponded to the expected variations; wild-type (HeLa) cells expressed detectable amounts of Ets-1, while HeLa-Ets-1 showed an increased and HeLa-invers a decreased Ets-1 expression ( Figure 1a ). Transactivation activity of the MMP-1 promoter, which contains functional Ets-1 binding sites (Dittmer, 2003) was correlated to these levels of expression; HeLa-Ets-1 cells showed an approximately doubling in transactivation compared to HeLa cells, while HeLa-invers cells showed a significantly repressed activity (70%) (Figure 1b ). These observations suggested that the properties of the established HeLa cell lines corresponded to the strategy adopted to produce them.
We first evaluated the effect of Ets-1 on cell migration using the wound assay. After 24 -30 h, the wounds were colonized to a much higher degree by HeLa-Ets-1 cells than HeLa and HeLa-invers cells (Figure 2a ), while no obvious differences could be observed at earlier time points (3, 6 and 9 h, data not shown). These differences in migration were not due to differences in cell proliferation as the three cell lines showed comparable proliferation rates (data not shown).
We next compared the invasive activity of the cells in the Matrigel invasion assay. HeLa-Ets-1 cells showed a 2.5-fold increase in invasive migration through the Matrigel compared to control HeLa and HeLa-invers cells, which had a comparable invasive behavior ( Figure 2b ). Such an increase of migration and invasion of HeLa-Ets-1 suggested a direct transforming effect of Ets-1.
In order to further address this point, we analysed the effect of Ets-1 on contact inhibition and clonal growth of cells in soft-agar-assay. As shown in Figure 2c HeLaEts-1 cells showed a stronger capacity for colony formation than HeLa and HeLa-invers cells, the latter two not being able to grow in an anchorage-independent way.
We then examined the influence of Ets-1 expression on attachment of HeLa cells. As illustrated in Figure 2d , Ets-1 underexpression correlated with lower adhesive properties, as nearly 80% of parental HeLa cells and 95% of HeLa-Ets-1 cells attached to a plastic surface after 2.5 h, whereas less than 50% of HeLa-invers cells were adhesive during the same period.
This latter observation finally prompted us to analyse the effect of Ets-1 on integrin receptor expression. Ets-1 expression did not affect the levels of integrinb3 (CD61), integrinb4 (CD 104), integrina6 (CD49f) or integrina3b1 (CD49c, Figure 3 ). However, there was a strong induction of integrinb2 (CD18) expression in HeLaEts-1 when compared to HeLa cells, while expression was undetectable in HeLa-invers cells (Figure 4) .
Our results, all taken together, show that Ets-1 promotes the migratory, invasive phenotype and anchorage-independent growth (the hallmark of all transformation) of neoplastic epithelial HeLa cells. This suggests that Ets-1 has a more complex role in tumors than previously proposed; in addition to its expression in tumor stroma, including endothelial cells, which is thought to help tumor growth by participating to tumor vascularization and invasion through the induction of proteases (Wernert et al., 1992 (Wernert et al., , 1994 Wernert, 1997; Behrens et al., 2001 Behrens et al., , 2003 and activation of endothelial cells, Ets-1 is shown here to play a direct role in promoting cell transformation.
Previous studies in normal epithelial MDCK cells had shown that Ets-1 expression was correlated to morphological changes induced by SF/HGF activation of a RAS-RAF-MEK-ERK pathway that activates Ets-1 (Fafeur et al., 1997; Paumelle et al., 2000 Paumelle et al., , 2002 . More recent data identified H19 as another target gene of this signalling pathway in MDCK cells (Adriaenssens et al., 2002) . However, since both H19 and Ets-1 are involved in morphogenesis and migration of epithelial cells, it is not clear which factor is responsible for the observed SF/HGF-induced effects. Our study specifically addressed Ets-1 effects and ruled out any indirect effect that could be mediated by activation of the RAS cascade. (Graham and van der Eb, 1973) . At 24 h after transfection, selection was started using 400 mg/ml G418 (Invitrogen). Cells were lysed by five freeze-thaw (room temperature) cycles. In all, 20 mg of total protein was analysed by 10% SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose (Bio-Rad). After blocking with 5% nonfat dry milk in PBS (Invitrogen) for 2 h at room temperature, filters were incubated in TBS-T (50 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.5) and with anti-Ets-1 rabbit polyclonal serum (1 : 1000; Transduction Laboratories), then with a horseradish peroxidase-conjugated secondary antibody (1 : 5000; Amersham Biosciences). Antibodies were detected using ECL reagents (Amersham Biosciences). The housekeeping protein b-actin, used as internal control, was detected using a mouse monoclonal anti-b-actin antibody (1 : 5000; Sigma). (b) In order to evaluate the Ets-1 transcriptional activity, the MMP-1 A/pGL2 plasmid (3 mg per well) bearing the luciferase gene under the control of the MMP-1 promoter (kindly provided by Ishii et al., 2003) was transfected into 1 Â 10 6 cells (per 35-mm well) as above, together with 3 mg of pCH110 (Amersham Pharmacia) normalization vector. Luciferase and b-galactosidase activity were measured using a luminometer (Berthold). The normalized luciferase activity measured in HeLa cells was set as 100%. The mean value of two independent experiments is shown. All differences were statistically significant at Po0.004
Ets-1 promotes epithelial cell transformation JC Hahne et al . After incubation at 371C for 22 h, the filters were removed and the cells adhering to the lower surface were fixed, stained with Hemacolor s (Merck) and counted. Differences between HeLa-Ets-1 and the two other cell lines were statistically significant at Po0.002. (c) Anchorage-independent growth (Soft-agar-assay). Cells (10 5 in DMEM, 20% FCS) were mixed with an equal volume of 0.8% agarose (FMC-BioProducts) and poured onto a bed of 1.4% agarose in culture plates. The culture medium was changed every 3 days and colony formation monitored (day 30, 43.75-fold magnification). (d) Attachment of HeLa cells. Cells (10 6 per well) were seeded into 10 cm 2 culture wells (Greiner Bio-one) and incubated at 371C. After 2.5 h, living cells in the supernatants were counted. The mean value of four independent experiments is shown. The difference between HeLa-Ets-1 and HeLa-invers was statistically significant at Po0.01 Figure 3 Expression of integrinb3, b4, a6 and a3b1 in the HeLa cell lines. Cells grown in 1 cm 2 culture chambers (Nunc) were rinsed once with PBS (Invitrogen), twice with 70% ethanol and fixed in a mixture of ice-cold methanol and ethanol (1 : 2 v : v, 41C, 20 min). After washing twice with PBS, cells were stained with antibodies (371C, 60 min) against integrinb4 (1 : 50, Novocastra Laboratories), integrin-a6 (1 : 100, DAKO), integrina3b1 (1 : 100, DAKO) or integrinb3 (1 : 100, DAKO). Primary antibodies were detected with the LSAB-peroxidase-system (DAKO, 30-fold magnification) MMP production is considered to be a marker for cancer cells with high metastatic potential (Liotta et al., 1980) , further, activated MMP-1 plays an important role in invasive activity of many cancer cells (Nishikawa et al., 2000; Behrens et al., 2001 Behrens et al., , 2003 . We observed that Ets-1 overexpression in HeLa cells activates the MMP-1 promoter, a somehow expected result since MMP-1 is a known ETS family target. However, we could not detect any MMP-1 overexpression in HeLaEts-1 cells using RT-PCR (data not shown), suggesting that Ets-1 expression is not sufficient to activate the endogenous mmp1 gene in these conditions. Besides MMP secretion, invasion requires cell migration involving coordinated swaps between cell detachment and substrate adhesion. Although Ets-1 overexpression increases cell invasiveness and migration, we also found that downregulation of Ets-1 represses cell attachment, suggesting that Ets-1 expression promotes adhesion. Cell attachment to the extracellular matrix is mainly mediated by binding of integrins to basement membrane and extracellular matrix ligands, including fibronectin (Ruoslahti, 1991) . Integrinmediated signalling after binding is not only involved in migration and invasion, but also in proliferation and apoptosis (Kumar, 1998; Danen and Yamada, 2001; Schwartz and Assoian, 2001; Maubant et al., 2002; Peterson, 2003) . We found that Ets-1 induces overexpression of integrinb2 in HeLa cells, but not of integrinsb3, b4, a6 and a3b1. This is quite interesting since the integrinb2 and b3 genes belong to a group of genes (integrinaIIb, aV, b2, b3 and b4) that contain ETS-binding sites in their promoters (Bottinger et al., 1994; Block et al., 1996; Tajima et al., 2000) . Thus, activation of these genes by Ets-1 was mostly expected; nevertheless, it was observed only for integrinb2, suggesting some level of specificity in the integrin genes that are targets of Ets-1 in HeLa cells, as already observed in endothelial cells (Sato, 1998) .
The main conclusion that can be drawn from our results is that Ets-1 promotes the transformed phenotype of HeLa cells, giving these cells anchorageindependent growth capabilities, which is an important feature of cancer cells. Induction of anchorage-independent growth seems to be a general effect of Ets-1 since it was already observed in NIH3T3 cells (Seth and Papas, 1990) . Together with the fact that Ets-1 is expressed in tumor stroma during tumor vascularization and together with different MMPs in stromal fibroblasts during invasion, our observations suggest that the Ets-1 transcription factor plays several distinct roles in tumor development and progression, acting both in neoplastic epithelial cells and in tumor stroma (Wernert et al., 1992 (Wernert et al., , 1994 Wernert, 1997; Behrens et al., 2001 Behrens et al., , 2003 .
